The haemodynamic effects of adjunctive hormone therapy in potential heart donors: A prospective randomized double-blind factorially designed controlled trial

European Heart Journal

Volumn 30, Issue 14, 2009, Pages 1771-1780

  Venkateswaran, Rajamiyer V ^a   Steeds, Richard P ^a   Quinn, David W ^a   Nightingale, Peter ^a   Wilson, Ian C ^a   Mascaro, Jorge G ^a   Thompson, Richard D ^a   Townend, Jonathan N ^a   Bonser, Robert S ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Donor management; Heart transplantation; Hormone replacement therapy

Indexed keywords

INOTROPIC AGENT; LIOTHYRONINE; METHYLPREDNISOLONE; NORADRENALIN; PLACEBO; VASOPRESSIN;

ADULT; ARTICLE; CARDIOVASCULAR FUNCTION; CENTRAL VENOUS PRESSURE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR SELECTION; DOUBLE BLIND PROCEDURE; FEMALE; HEART DISEASE; HEART EJECTION FRACTION; HEART INDEX; HEART OUTPUT; HEART STROKE VOLUME; HEART TRANSPLANTATION; HEMODYNAMICS; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE;

ADULT; CARDIAC OUTPUT; CARDIOTONIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; GREAT BRITAIN; HEART; HEMODYNAMICS; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROSPECTIVE STUDIES; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TRIIODOTHYRONINE;

EID: 67651089962     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp086     Document Type: Article

References (39)

1. Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB. Care of the potential organ donor. N Engl J Med 2004;351:2730-2739.
2. Novitzky D, Horak A, Cooper DK, Rose AG. Electrocardiographic and histopathologic changes developing during experimental brain death in the baboon. Transplant Proc 1989;21(1 Pt III):2567-2569.
3. Powner DJ, Hendrich A, Lagler RG, Ng RH, Madden RL. Hormonal changes in brain dead patients. Crit Care Med 1990;18:702-708.
4. Mariot J, Sadoune LO, Jacob F, Dousset B, Perrier JF, Jacob C, Strub P, Voltz C. Hormone levels, hemodynamics, and metabolism in brain dead organ donors. Transplant Proc 1995;27:793-794.
5. Masson F, Thicoipe M, Latapie MJ, Maurette P. Thyroid function in brain-dead donors. Transpl Int 1990;3:226-233.
6. Novitzky D. Triiodothyronine replacement, the euthyroid sick syndrome, and organ transplantation. Transplant Proc 1991;23:2460-2462.
7. Rosendale JD, Kauffman HM, McBride MA, Chabalewski FL, Zaroff JG, Garrity ER, Delmonico FL, Rosengard BR. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003;75:482- 487.
8. Rosendale JD, Kauffman HM, McBride MA, Chabalewski FL, Zaroff JG, Garrity ER, Delmonico FL, Rosengard BR. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation 2003;75:1336-1341.
9. Smith M. Physiologic changes during brain stem death-lessons for management of the organ donor. J Heart Lung Transplant 2004;23(9 Suppl.):S217-S222.
10. Novitzky D, Cooper DK, Chaffin JS, Greer AE, DeBault LE, Zuhdi N. Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. Transplantation 1990;49:311-316.
11. Jeevanandam V, Todd B, Hellman S, Eldridge C, McClurken J, Addonizio VP. Use of triiodothyronine replacement therapy to reverse donor myocardial dysfunction: creating a larger donor pool. Transplant Proc 1993;25:3305-3306.
12. Goarin JP, Cohen S, Riou B, Jacquens Y, Guesde R, Le Bret F, Aurengo A, Coriat P. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg 1996;83:41-47.
13. Randell TT, Hockerstedt KA. Triiodothyronine treatment in brain-dead multiorgan donors-a controlled study. Transplantation 1992;54:736-738.
14. Wan S, DeSmet JM, Antoine M, Goldman M, Vincent JL, LeClerc JL. Steroid administration in heart and heart-lung transplantation: is the timing adequate? Ann Thorac Surg 1996;61:674-678.
15. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant 1998;17:423-429.
16. Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 1995;333:1522-1527.
17. Ranasinghe AM, Quinn DW, Pagano D, Edwards N, Faroqui M, Graham TR, Keogh BE, Mascaro J, Riddington DW, Rooney SJ, Townend JN, Wilson IC, Bonser RS. Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting. Circulation 2006;114(1 Suppl.):I245-I250.
18. Potter CD, Wheeldon DR, Wallwork J. Functional assessment and management of heart donors: a rationale for characterization and a guide to therapy. J Heart Lung Transplant 1995;14(1 Pt 1):59-65.
19. Wheeldon DR, Potter CD, Oduro A, Wallwork J, Large SR. Transforming the 'unacceptable' donor: outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant 1995;14:734-742.
20. Wahlers T, Cremer J, Fieguth HG, Dammenhayn L, Albes J, Schafers HJ, Haverich A, Borst HG. Donor heart-related variables and early mortality after heart transplantation. J Heart Lung Transplant 1991;10(1 Pt 1):22-27.
21. Stoica SC, Satchithananda DK, Atkinson C, White PA, Redington AN, Goddard M, Kealey T, Large SR. The energy metabolism in the right and left ventricles of human donor hearts across transplantation. Eur J Cardiothorac Surg 2003; 23:503-512.
22. Gramm HJ, Meinhold H, Bickel U, Zimmermann J, von Hammerstein B, Keller F, Dennhardt R, Voigt K. Acute endocrine failure after brain death? Transplantation 1992;54:851-857.
23. Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation 2006; 82:1396-1401.
24. Novitzky D, Cooper DK. Results of hormonal therapy in human brain-dead potential organ donors. Transplant Proc 1988;20(5 Suppl. 7):59-62.
25. Jeevanandam V, Todd B, Regillo T, Hellman S, Eldridge C, McClurken J. Reversal of donor myocardial dysfunction by triiodothyronine replacement therapy. J Heart Lung Transplant 1994;13:681-687.
26. Rosendale JD, Chabalewski FL, McBride MA, Garrity ER, Rosengard BR, Delmonico FL, Kauffman HM. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant 2002;2:761-768.
27. Jeevanandam V. Triiodothyronine: spectrum of use in heart transplantation. Thyroid 1997;7:139-145.
28. Timek T, Vahl CF, Bonz A, Schaffer L, Rosenberg M, Hagl S. Triiodothyronine reverses depressed contractile performance after excessive catecholamine stimulation. Ann Thorac Surg 1998;66:1618-1625.
29. Taniguchi S, Kitamura S, Kawachi K, Doi Y, Aoyama N. Effects of hormonal supplements on the maintenance of cardiac function in potential donor patients after cerebral death. Eur J Cardiothorac Surg 1992;6:96-101.
30. Zuppa AF, Nadkarni V, Davis L, Adamson PC, Helfaer MA, Elliott MR, Abrams J, Durbin D. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med 2004; 32:2318-2322.
31. Chen JM, Cullinane S, Spanier TB, Artrip JH, John R, Edwards NM, Oz MC, Landry DW. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation 1999;100(19 Suppl.):II244-II246.
32. Pennefather SH. Effects of triiodothyronine and vasopressin on cardiac function and myocardial blood flow after brain death. J Heart Lung Transplant 1993;12:889-890.
33. Yoshioka T, Sugimoto H, Uenishi M, Sakamoto T, Sadamitsu D, Sakano T, Sugimoto T. Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosurgery 1986;18:565-567.
34. Bosso FJ, Allman FD, Pilati CF. Myocardial work load is a major determinant of norepinephrine-induced left ventricular dysfunction. Am J Physiol Heart Circ Physiol 1994;266:H531-H539.
35. Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation 1995;59:58-62.
36. Stoica SC, Satchithananda DK, White PA, Parameshwar J, Redington AN, Large SR. Noradrenaline use in the human donor and relationship with load-independent right ventricular contractility. Transplantation 2004;78: 1193-1197.
37. Schnuelle P, Berger S, De Boer J, Persijn G, Van derWoude FJ, Hickman R. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation 2001;72:362-363.
38. Chen EP, Bittner HB, Kendall SW, Van Trigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med 1996;24: 1352-1359.
39. Kinoshita Y, Okamoto K, Yahata K, Yoshioka T, Sugimoto T, Kawaguchi N, Onishi S. Clinical and pathological changes of the heart in brain death maintained with vasopressin and epinephrine. Pathol Res Pract 1990;186:173-179.